|
Chairperson: Alan J. Thompson, London, United Kingdom The ever-increasing number of therapeutic options now available in multiple sclerosis (MS) has transformed patient management but has also added a new layer of complexity. Utilising these treatments in an appropriate and effective manner requires a sound understanding of when and how they should be introduced informed by a comprehensive knowledge of their efficacy and their side-effect profile. This session describes an up to date understanding of our use of all the agents available to us in the treatment of MS, including the concept of first and second line treatments, symptomatic management and importantly the complex safety and side-effect profile. |
||
| Overview symptom management (motor disturbance, spasticity and fatigue) |
Alan J. Thompson London, United Kingdom |
 |
| First-line disease modifying treatments (when to start/stop?) |
Xavier Montalban Barcelona, Spain |
|
| Second line / switching and combination DMTs |
Bernd C. Kieseier Düsseldorf, Germany |
|
| Complications and safety |
Aksel Siva Istanbul - Cerrahpasa, Turkey |
|